Sector News

Stryker acquires single-use device reprocessor Hygia Health Services

May 2, 2018
Life sciences

Stryker said today it acquired single-use-device reprocessor Hygia Health Services for an undisclosed amount.

Birmingham, Ala.-based Hygia has partnered with Kalamazoo, Mich.-based Stryker since 2015 to reprocess single-use devices, and Stryker said the acquisition will “further solidify the partnership.”

Stryker said that Hygia’s product portfolio of air transfer mattresses, fall alarms, ECG leads, cerebral-somatic sensors and infusor bags will help broaden its reprocessing offerings. Stryker said that it reprocessed approximately 3,000 single-use devices in 2017, with estimated savings of approximately $326 million.

“In line with our commitment to help hospitals and health systems increase the value their SUD reprocessing programs deliver, this acquisition will enhance our ability to deliver savings to our customers. Furthermore, our broader product portfolio will help customers elevate their sustainability goals and set a higher bar for sustainable healthcare delivery,” Stryker sustainability solutions prez Brian White said in a prepared statement.

Last week, Stryker saw shares fall slightly after it posted first quarter earnings that topped Wall Street expectations but saw sales shrink slightly.

By Fink Densford

Source: MassDevice

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach